{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:22:14Z","timestamp":1759710134304,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013059","name":"Jiangsu Provincial Medical Youth Talent","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013059","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychoneuroendocrinology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.psyneuen.2019.06.017","type":"journal-article","created":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T10:35:38Z","timestamp":1562409338000},"page":"163-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Metabolic and endocrinal effects of N-desmethyl-olanzapine in mice with obesity: Implication for olanzapine-associated metabolic changes"],"prefix":"10.1016","volume":"108","author":[{"given":"Xueli","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.psyneuen.2019.06.017_bib0005","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pharmthera.2018.06.012","article-title":"Molecular targets of atypical antipsychotics: from mechanism of action to clinical differences","volume":"192","author":"Aringhieri","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0010","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamapsychiatry.2013.2053","article-title":"Antipsychotics and the risk of type 2 diabetes mellitus in children and youth","volume":"70","author":"Bobo","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0015","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tips.2010.07.002","article-title":"Preclinical models of antipsychotic drug-induced metabolic side effects","volume":"31","author":"Boyda","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0020","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1242\/jeb.050989","article-title":"Nonshivering thermogenesis and its adequate measurement in metabolic studies","volume":"214","author":"Cannon","year":"2011","journal-title":"J. Exp. Biol."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0025","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/acps.12794","article-title":"Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine","volume":"136","author":"Castberg","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0030","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.schres.2013.09.017","article-title":"A population-based cohort study to elucidate temporal relationship between schizophrenia and metabolic syndrome (KCIS no. PSY3)","volume":"151","author":"Chang","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0035","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1038\/s41467-018-07287-7","article-title":"Serotonin signals through a gut-liver axis to regulate hepatic steatosis","volume":"9","author":"Choi","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0040","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nm.3766","article-title":"Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis","volume":"21","author":"Crane","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0045","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/YIC.0000000000000052","article-title":"Increased lean body mass as an early indicator of olanzapine-induced weight gain in healthy men","volume":"30","author":"Daurignac","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0050","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00213-011-2555-2","article-title":"Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters","volume":"221","author":"Davey","year":"2012","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0960-894X(96)00567-7","article-title":"The synthesis and biological activity of some known and putative metabolites of the atypical antipsychotic agent olanzapine (LY170053)","volume":"7","author":"David O Calligaro","year":"1997","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0060","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.tem.2019.03.002","article-title":"Adipocyte metabolism and insulin signaling perturbations: insights from genetics","volume":"30","author":"Friesen","year":"2019","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0065","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.psyneuen.2019.03.017","article-title":"Olanzapine-induced endoplasmic reticulum stress and inflammation in the hypothalamus were inhibited by an ER stress inhibitor 4-phenylbutyrate","volume":"104","author":"He","year":"2019","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0070","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S2215-0366(15)00115-7","article-title":"Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses","volume":"2","author":"Henderson","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0075","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.psyneuen.2016.07.218","article-title":"Olanzapine-depot administration induces time-dependent changes in adipose tissue endocrine function in rats","volume":"73","author":"Horska","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0080","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/0269881117691466","article-title":"Depot risperidone-induced adverse metabolic alterations in female rats","volume":"31","author":"Horska","year":"2017","journal-title":"J. Psychopharmacol. (Oxford)"},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0085","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.2337\/db13-0804","article-title":"Unraveling the mechanisms underlying olanzapine-induced insulin resistance","volume":"62","author":"Irwin","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0090","first-page":"81","article-title":"Disposition and biotransformation of the antipsychotic agent olanzapine in humans","volume":"25","author":"Kassahun","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0095","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.psyneuen.2014.06.010","article-title":"Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways","volume":"48","author":"Lian","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0100","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1172\/JCI93362","article-title":"The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C","volume":"127","author":"Lord","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0105","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.schres.2017.07.022","article-title":"Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor metabolic parameters in patients with schizophrenia","volume":"193","author":"Lu","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0110","article-title":"Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters","volume":"8","author":"Lu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0115","article-title":"Application of plasma levels of olanzapine and N-Desmethyl-Olanzapine to monitor clinical efficacy in patients with schizophrenia","volume":"11","author":"Lu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0120","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/jnc.13582","article-title":"Dopamine D2 and serotonin 5-HT1A receptor interaction in the context of the effects of antipsychotics - in vitro studies","volume":"137","author":"Lukasiewicz","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0125","first-page":"573","article-title":"Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys","volume":"25","author":"Mattiuz","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0130","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1517\/14740338.2015.974549","article-title":"Weight gain and antipsychotics: a drug safety review","volume":"14","author":"Musil","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0135","doi-asserted-by":"crossref","first-page":"6794","DOI":"10.1038\/ncomms7794","article-title":"Regulation of systemic energy homeostasis by serotonin in adipose tissues","volume":"6","author":"Oh","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0140","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0145","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/bcp.13480","article-title":"Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation","volume":"84","author":"Polasek","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0150","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","author":"Swanson","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0155","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/01.ftd.0000249950.75462.7f","article-title":"Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication","volume":"28","author":"Theisen","year":"2006","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0160","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.psyneuen.2017.12.004","article-title":"Obesity exacerbates the acute metabolic side effects of olanzapine","volume":"88","author":"Townsend","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0165","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1017\/S146114571300093X","article-title":"Modelling olanzapine-induced weight gain in rats","volume":"17","author":"van der Zwaal","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0170","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/FBP.0b013e328348ec4f","article-title":"The metabolites N-desmethylclozapine and N-desmethylolanzapine produce cross-tolerance to the discriminative stimulus of the atypical antipsychotic clozapine in C57BL\/6 mice","volume":"22","author":"Wiebelhaus","year":"2011","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0175","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/mp.2015.158","article-title":"Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: a CANMAT randomized double-blind trial","volume":"21","author":"Yatham","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0180","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/JCP.0000000000000770","article-title":"A pilot study of the usefulness of a single olanzapine plasma concentration as an Indicator of early drug effect in a small sample of first-episode psychosis patients","volume":"37","author":"Zabala","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2019.06.017_bib0185","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.bcp.2018.10.001","article-title":"Regulation of obesity-associated metabolic disturbance by the antipsychotic drug olanzapine: role of the autophagy-lysosome pathway","volume":"158","author":"Zhang","year":"2018","journal-title":"Biochem. Pharmacol."}],"container-title":["Psychoneuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453019304391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453019304391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T17:06:37Z","timestamp":1759683997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306453019304391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":37,"alternative-id":["S0306453019304391"],"URL":"https:\/\/doi.org\/10.1016\/j.psyneuen.2019.06.017","relation":{},"ISSN":["0306-4530"],"issn-type":[{"type":"print","value":"0306-4530"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic and endocrinal effects of N-desmethyl-olanzapine in mice with obesity: Implication for olanzapine-associated metabolic changes","name":"articletitle","label":"Article Title"},{"value":"Psychoneuroendocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psyneuen.2019.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}